Literature DB >> 21350101

DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks.

Dick G Hwang1, Xiaohua Qian, Jason L Hornick.   

Abstract

Initial diagnosis of submucosal gastrointestinal stromal tumors (GISTs) is often made from material obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). Although 95% of GISTs are positive for KIT by immunohistochemical analysis on surgical specimens, we have observed several cases of GIST that were negative for KIT on the cell block but subsequently positive on the surgical resection. DOG1 has been found to be a specific and sensitive marker for GISTs on surgical material. We compared KIT and DOG1 staining in 52 GIST cell blocks and in 44 cell blocks of other intra-abdominal spindle cell neoplasms. We found that DOG1 was the more sensitive marker, with positivity in all 52 GIST cell blocks. KIT was positive in 46 (88%) of the GIST cases, with sensitivity dependent on the FNA method. Both markers were highly specific: KIT was negative in all 44 non-GIST cases, whereas DOG1 showed weak positivity in only 1 leiomyosarcoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350101     DOI: 10.1309/AJCP0PPKOBNDT9LB

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  22 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXXV: calcium-activated chloride channels.

Authors:  Fen Huang; Xiuming Wong; Lily Y Jan
Journal:  Pharmacol Rev       Date:  2011-11-16       Impact factor: 25.468

2.  Diagnosis value of CD117 and PDGFRA, alone or in combination DOG1, as biomarkers for gastrointestinal stromal tumors.

Authors:  Chunwei Xu; Hongyan Han; Jingjing Wang; Bo Zhang; Yun Shao; Liying Zhang; Huaitao Wang; Haiyan Wang; Yongfang Wu; Xiaobing Li; Ruiming Li; Yuwang Tian
Journal:  Ann Transl Med       Date:  2015-11

3.  Relationship of endothelial area with VEGF-A, COX-2, maspin, c-KIT, and DOG-1 immunoreactivity in liposarcomas versus non-lipomatous soft tissue tumors.

Authors:  Ioan Jung; Simona Gurzu; Sabin Turdean; Diana Ciortea; Danut Ioan Sahlean; Mircea Golea; Tivadar Bara
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 4.  Physiological roles and diseases of Tmem16/Anoctamin proteins: are they all chloride channels?

Authors:  Charity Duran; H Criss Hartzell
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

5.  Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery.

Authors:  Y He; H Li; Y Chen; P Li; L Gao; Y Zheng; Y Sun; J Chen; X Qian
Journal:  Clin Transl Oncol       Date:  2017-03-15       Impact factor: 3.405

6.  Role of cytopathology in the diagnosis and management of gastrointestinal tract cancers.

Authors:  Rachel Conrad; Camilla Cobb; Anwar Raza
Journal:  J Gastrointest Oncol       Date:  2012-09

7.  Synchronous Appearance of Adenocarcinoma and Gastrointestinal Stromal Tumour (GIST) of the Stomach: A Case Report.

Authors:  Ramesh Babu Telugu; Magesh Pushparaj; Dipti Masih; Anna Pulimood
Journal:  J Clin Diagn Res       Date:  2016-02-01

8.  DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach.

Authors:  Takuya Wada; Satoshi Tanabe; Kenji Ishido; Katsuhiko Higuchi; Tohru Sasaki; Chikatoshi Katada; Mizutomo Azuma; Akira Naruke; Myunguchul Kim; Wasaburo Koizumi; Tetsuo Mikami
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

9.  Pathology of gastrointestinal stromal tumors.

Authors:  Wai Chin Foo; Bernadette Liegl-Atzwanger; Alexander J Lazar
Journal:  Clin Med Insights Pathol       Date:  2012-07-17

10.  Enhanced expression of ANO1 in head and neck squamous cell carcinoma causes cell migration and correlates with poor prognosis.

Authors:  Christian Ruiz; Joana Raquel Martins; Florian Rudin; Sandra Schneider; Tanja Dietsche; Claude A Fischer; Luigi Tornillo; Luigi M Terracciano; Rainer Schreiber; Lukas Bubendorf; Karl Kunzelmann
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.